文献速递淋巴瘤浆细胞疾病

转化的华氏巨球蛋白血症:临床表现与结局——法国创新白血病组织(FILO)77例多机构回顾性研究

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
PubMed 文献 · Br J Haematol · 2017-08-02

该多机构回顾性研究纳入77例经活检证实转化为弥漫大B细胞淋巴瘤(DLBCL)的华氏巨球蛋白血症(WM)患者,中位转化时间4.6年,21%患者从未接受WM治疗;转化后91%累及结外,一线以R-CHOP样方案为主,总缓解率61%,中位总生存仅16个月;转化时间超过5年(P=0.0004)和LDH升高(P=0.02)与更差结局相关。

要点

  • WM患者出现结外受累、LDH升高和全身症状时应考虑组织学转化并活检。
  • 转化后一线治疗85%为R-CHOP样方案,总缓解率61%,中位总生存16个月。
  • 转化时间超过5年(P=0.0004)和LDH升高(P=0.02)与更差结局相关。

核心结论

  • WM患者出现结外受累、LDH升高和全身症状时应考虑组织学转化并活检。
  • 转化的最佳治疗策略仍有待明确。

研究设计与样本

  • 法国创新白血病组织(FILO)开展的多机构回顾性研究,纳入77例经活检证实转化为DLBCL的WM患者。

主要发现

  • 从WM诊断到组织学转化的中位时间为4.6年,16例(21%)患者从未接受过WM治疗。
  • 转化时91%的患者出现结外部位受累,中枢神经系统、皮肤或睾丸受累发生率较高。
  • 半数患者进行了氟脱氧葡萄糖-正电子发射断层扫描,转化病变的中位最大标准化摄取值(SUVmax)为15。
  • 在可用Hans算法评估的病例中,超过80%为非生发中心B细胞表型。
  • 转化后一线治疗85%为R-CHOP(利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松)样方案,一线治疗后总缓解率为61%,整个队列的中位总生存仅16个月。

临床怎么用

  • 作者认为,WM患者出现结外受累、LDH升高和全身症状时应考虑组织学转化并活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4·6 years and 16 patients (21%) had never been treated for WM. At HT, extranodal sites were observed in 91% of patients with a rather high incidence of central nervous system, cutaneous or testicular involvement. Fluorodeoxyglucose-positron emission tomography was performed in half of the patients and the median maximum standardized uptake value was 15 for transformed disease. More than 80% of cases with available data for assessment by the Hans' algorithm harboured a non-germinal centre B-cell phenotype. First-line treatment for transformation consisted of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)-like regimen in 85% of patients. The overall response rate after first-line treatment was 61% and the median overall survival was only 16 months for the entire cohort. Time to transformation above 5 years (P = 0·0004) and elevated LDH (P = 0·02) were associated with worse outcome. Based on these findings, HT should be considered and lead to a biopsy in WM patients presenting with extranodal involvement, elevated LDH and constitutional symptoms. The optimal therapeutic approaches remain to be defined.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Durot E, Tomowiak C, Michallet AS, et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017. PMID: 28770576. doi:10.1111/bjh.14881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。